Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReproductive Health & FertilityBaylor Scott & White Health Plan Fertility Coverag…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBaylor Scott & White Health PlanPolicy 141

    Infertility, Fertility Preservation, Assisted Reproductive Technology

    Customize your policy alerts

    Sign up for Baylor Scott & White Health Plan Policy 141 alerts

    Get alerted when Policy 141 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, coverage stance, and required prior authorization for infertility evaluation, fertility preservation for iatrogenic infertility (notably cancer-related), and associated assisted reproductive technology services for members of Baylor Scott & White Health Plan.

    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyInfertility, Fertility Preservation, Assisted Reproductive Technology
    Policy CodePolicy 141
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 23, 2026
    Next Review DateApr 23, 2027
    Key ActionObtain prior authorization for fertility preservation requests and include diagnosis code Z31.84 with documentation of planned gonadotoxic cancer treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Prior authFertility preservation services
    IVF onlyInfertility treatment limits
    Z31.84Required diagnosis code
    >20 itemsExperimental services
    05/01/2026Effective
    04/23/2027Next review

    Coverage Criteria

    Iatrogenic Fertility Preservation (Cancer-related)

    BSWHP may consider Fertility Preservation services medically necessary when ALL of the following are met:

    Iatrogenic fertility preservation criteria: 1) The fertility preservation procedure is a standard procedure consistent with ASCO or ASRM guidelines; AND 2) The request is submitted with diagnosis code Z31.84 (Encounter for fertility preservation procedure); AND 3) The member has a diagnosis of cancer; AND 4) The member has one of the following planned treatments that may directly or indirectly cause impaired fertility: a) chemotherapy with intermediate/high risk per Appendices A & B, OR b) pelvic, abdominal, cranio-spinal, or total body irradiation, OR c) surgical treatment that may produce anatomic or vascular changes to reproductive organs or adjacent structures; AND 5) There is planned cryopreservation of unfertilized oocytes or sperm; AND 6) The member is within the covered age/sexual maturity groups: post-pubertal or adult male, or pre-pubertal, post-pubertal (menarche), or pre-menopausal adult female.

    Diagnostic Evaluation of Infertility

    BSWHP may consider infertility and reproductive technology medically necessary for diagnostic evaluation when performed stepwise:

    Diagnostic evaluation:
    Policy Summary
    PayerBaylor Scott & White Health Plan
    PolicyInfertility, Fertility Preservation, Assisted Reproductive Technology
    Policy CodePolicy 141
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Last ReviewApr 23, 2026
    Next Review DateApr 23, 2027
    Key ActionObtain prior authorization for fertility preservation requests and include diagnosis code Z31.84 with documentation of planned gonadotoxic cancer treatment.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions and Authorization RequirementsDefinitionsBackgroundRevision History
    Evaluation may include history and physical examination; laboratory testing (female: TSH, prolactin, FSH, LH, estradiol, progesterone; male: endocrine testing including FSH, total and free testosterone, prolactin, LH, TSH, and other indicated assays); pelvic ultrasound; hysteroscopy; hysterosalpingography; sonohysterography; diagnostic laparoscopy with or without chromotubation; and male evaluation including semen analysis (volume, concentration, motility, pH, fructose, leukocyte count, microbiology, morphology), transrectal or scrotal ultrasound, vasography, and testicular biopsy. Testing should be performed in a stepwise fashion based on history and prior results rather than all tests at once.

    Scoped covered services (code-based)

    Covered services and relevant diagnoses are identified by listed HCPCS and ICD-10 codes.

    Code-based coverage: Services described by the listed S4xxx HCPCS case-rate and related service codes (e.g., S4022, S4023, S4025, S4026, S4027, S4028, S4030, S4031, S4035, S4037, S4040, S4042) and the CPT/HCPCS procedure codes referenced in the policy are within the scope of this policy when supported by corresponding infertility-related ICD-10 diagnosis/encounter codes (including N46.*; N97.*; Z31.41, Z31.81, Z31.84).

    Full clinical medical necessity prerequisites are specified elsewhere in the policy (see Iatrogenic Fertility Preservation and Diagnostic Evaluation sections).

    Most Baylor Scott & White Health Plan members have coverage for the diagnostic evaluation of infertility but treatment of infertility is not a benefit for most plans unless specifically purchased as a rider. Where infertility treatment is a covered benefit under a plan, interventions are typically limited to in vitro fertilization (IVF). Prior authorization is required for fertility preservation services, and fertility preservation and storage of reproductive material may not be a benefit for some plans; when covered, services may be limited to standard retrieval, isolation, and cryopreservation. Hormonal therapies/medications and storage of unfertilized genetic materials may be excluded depending on the member's benefit document.

    The excerpt reviewed does not contain a separate, fully detailed exclusions section within these chunks. The policy history notes prior updates (including corrected exclusions and clarifications added in 2024–2025) but the specific exclusion language beyond the summary that treatment is not a benefit for most plans appears only in the plan-level Evidence of Coverage (EOC) or SPD; reviewers should refer to those member-specific documents for the definitive exclusion and limitation text.

    Policies referencing state or legislative requirements and prior revisions are documented in the policy update log; any plan-level application of exclusions or riders should be confirmed against the applicable EOC/SPD and the policy change history.

    The policy identifies a number of services that BSWHP considers experimental, investigational, or unproven for the treatment or evaluation of infertility. Examples listed include: acupuncture; hyperbaric oxygen therapy for IVF; intravaginal culture devices (e.g., INVOcell); various immune treatments (peri-implantation glucocorticoids, anti‑TNF agents, leukocyte immunization, IVIG); computer-assisted sperm motion analysis; co‑culture techniques for embryo/oocyte culture; direct intraperitoneal or intrafollicular insemination; endometrial receptivity testing (e.g., Endometrial Function Test™, ERA); fine needle aspiration mapping; hemizona test; hyaluronan binding assay; sperm viability tests when used diagnostically; use of sperm precursors; manual soft tissue therapies for pelvic adhesions; laser removal of necrotic blastomeres from cryopreserved embryos; reactive oxygen species testing; time-lapse embryo imaging (e.g., EmbryoScope); uterine transplantation; vaginal microbiome testing; and saline-air infused sono-hysterosalpingogram variants (e.g., femVue®).

    Within the provided excerpt there are no explicit statements formatted as ‘not medically necessary’ for specific services beyond the list of experimental or investigational items. The policy change log indicates prior revisions and corrections to exclusions, suggesting editorial updates have been made in earlier versions, but the reviewed chunks do not include separate, formalized 'not medically necessary' language; determination of not medically necessary should follow the policy criteria and member plan benefits.

    Coding and Billing Codes

    CPT Codes (selected)CPT
    54500Biopsy of testis, needle (separate procedure)
    54505Biopsy of testis, incisional (separate procedure)
    54800Biopsy of epididymis, needle
    55200Vasotomy, cannulization with or without incision of vas, unilateral or bilateral (separate procedure)
    55870Electroejaculation*
    58970Follicle Puncture for Oocyte retrieval, any Method (IVF)*
    58974Embryo transfer, intrauterine
    58976Gamete, zygote, or embryo intrafallopian transfer, any method
    76948Ultrasonic guidance for aspiration of ova, imaging supervision and interpretation*
    83001Gonadotropin; follicle stimulating hormone (FSH)
    1–10 of 29
    1/3
    CPT Codes (cryopreservation & storage)CPT
    89337Cryopreservation, mature oocyte(s)*
    89342Storage, (per year) for embryo(s)
    89344Storage, (per year) for reproductive tissue, testicular/ovarian
    89346Storage, (per year) for oocyte(s)
    89352Thawing of cryopreserved; embryo(s)
    89353Thawing of cryopreserved; sperm/semen, each aliquot
    89354Thawing of cryopreserved; reproductive tissue, testicular/ovarian
    HCPCS / Drugs / S-codes (selected)mixed
    0058TCryopreservation; reproductive tissue, ovarian*
    G0027Semen analysis; presence and/or motility of sperm excluding Huhner
    J0725Injection, chorionic gonadotropin, per 1,000 USP units
    J3355Injection, urofollitropin, 75 IU
    Q0115Postcoital direct, qualitative examinations of vaginal or cervical mucous
    S0122Injection, menotropins, 75 IU
    S0126Injection, follitropin alfa, 75 IU
    S0128Injection, follitropin beta, 75 IU
    S0132Injection, ganirelix acetate, 250 mcg
    S4011In vitro fertilization; including but not limited to identification and incubation of mature oocytes, fertilization with sperm, incubation of embryo(s), and subsequent visualization for determination of development
    1–10 of 18
    1/2
    ICD-10 CodesICD-10
    N46.01Organic azoospermia
    N46.021Azoospermia due to drug therapy
    N46.022Azoospermia due to infection
    N46.023Azoospermia due to obstruction of efferent ducts
    N46.024Azoospermia due to radiation
    N46.025Azoospermia due to systemic disease
    N46.029Azoospermia due to other extratesticular causes
    N46.11Organic oligospermia
    N46.121Oligospermia due to drug therapy
    N46.122Oligospermia due to infection
    1–10 of 25
    1/3
    Covered S4xxx and related service codesHCPCSCovered
    S4022Assisted oocyte fertilization, case rate
    S4023Donor egg cycle, incomplete, case rate
    S4025Donor services for in vitro fertilization (sperm or embryo), case rate
    S4026Procurement of donor sperm from sperm bank
    S4027Storage of previously frozen embryos
    S4028Microsurgical epididymal sperm aspiration (MESA)
    S4030Sperm procurement and cryopreservation services; initial visit
    S4031Sperm procurement and cryopreservation services; subsequent visit
    S4035Stimulated intrauterine insemination (IUI), case rate
    S4037Cryopreserved embryo transfer, case rate
    1–10 of 12
    1/2
    Relevant ICD-10 diagnosis and encounter codesICD-10
    E23.0-Hypopituitarism (ICD10 example listed)
    N46.01Organic azoospermia
    N46.021Azoospermia due to drug therapy
    N46.022Azoospermia due to infection
    N46.023Azoospermia due to obstruction of efferent ducts
    N46.024Azoospermia due to radiation
    N46.025Azoospermia due to systemic disease
    N46.029Azoospermia due to other extratesticular causes
    N46.11Organic oligospermia
    N46.121Oligospermia due to drug therapy
    1–10 of 26
    1/3

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for fertility preservation services. Failure to obtain prior authorization for these services may result in claim denial. Genetic/genomic testing may also require prior authorization.

    • Prior authorization required for fertility preservation services (including iatrogenic fertility preservation).
    • Genetic / genomic testing may require prior authorization.
    Step Therapy

    Stepwise Diagnostic Evaluation

    Evaluation for infertility is expected to be performed in a stepwise fashion based on patient history and prior test results; not all tests are necessary for every individual. Testing and diagnostic procedures should follow the clinical pathway appropriate to the presenting history.

    • Stepwise diagnostic evaluation — order tests based on history and prior results; avoid reflexive full-panel testing for every patient.
    • Male evaluation examples: history and physical exam; semen analysis (volume, concentration, motility, pH, fructose, leukocyte count, microbiology, morphology); endocrine testing (FSH, total and free testosterone, prolactin, LH, TSH); transrectal/scrotal ultrasound; vasography/testicular biopsy when indicated.
    • Female evaluation examples: history and physical exam; laboratory tests (TSH, prolactin, FSH, LH, estradiol, progesterone); pelvic ultrasound; hysteroscopy; hysterosalpingography; sonohysterography; diagnostic laparoscopy with or without chromotubation.
    Documentation Required

    Iatrogenic Fertility Preservation Documentation and Coding

    Requests for iatrogenic fertility preservation must include the diagnosis code Z31.84 (Encounter for fertility preservation procedure) and supporting clinical documentation demonstrating the member has a diagnosis (e.g., cancer) and planned treatment that places them at risk for impaired fertility (chemotherapy, radiotherapy, or surgery). Documentation should also support the specific procedure(s) being requested and the applicable procedure/ICD-10 codes billed.

    • Submit requests with ICD-10 code Z31.84 when for fertility preservation related to planned medical treatment.
    • Include supporting documentation: cancer diagnosis, planned treatment details (e.g., chemo regimen, radiation fields/dose, planned surgery) and rationale linking treatment to risk of impaired fertility.
    • Documentation must support use of listed S4xxx case-rate codes and related procurement, storage, donor, and microsurgical service codes; claims may be denied if billed with codes not listed or outside covered services.

    Definitions

    Infertility — definition and diagnostic timeframes
    DefinitionThe inability to conceive or carry a pregnancy to live birth after unprotected intercourse without contraception — 12 months if under age 35, or 6 months if age 35 years or older.
    Alternative justificationInfertility may also be justified when an individual has a medical or other recognized condition as the cause of infertility.
    Earlier evaluationEvaluation may be initiated sooner for patients with risk factors for infertility.
    Iatrogenic Infertility — definition and coverage triggers
    DefinitionIatrogenic (medically induced) infertility occurs as a result of a medical procedure performed to treat another problem, most often cancer treated with chemotherapy or radiation.
    Coverage triggerFertility preservation may be medically necessary for males and females facing iatrogenic infertility from cancer treatments (chemotherapy, radiotherapy, or surgery) when criteria are met per ASCO/ASRM-consistent procedures.
    Required documentationRequests must be submitted with diagnosis code Z31.84 (Encounter for fertility preservation procedure) and supporting evidence of planned gonadotoxic treatment and cancer diagnosis.
    Infertility diagnoses and encounter codes
    Female infertility ICD-10 codesN97.0, N97.1, N97.2, N97.8, N97.9 (female infertility by cause or unspecified)
    Male infertility ICD-10 codesN46.01, N46.021, N46.022, N46.023, N46.024, N46.025, N46.029, N46.11, N46.121, N46.122, N46.123, N46.124, N46.125, N46.129, N46.8, N46.9
    Fertility testing / preservation encounter codesZ31.41 (female fertility testing), Z31.81 (male fertility testing), Z31.84 (encounter for fertility preservation procedure)
    Chemotherapy agents associated with intermediate/high fertility risk (Appendices A & B)
    Appendix A — female agents (examples)Lists chemotherapeutic agents associated with intermediate/high risk to female fertility (examples: busulfan; carboplatin; carmustine; chlorambucil; cisplatin; doxorubicin; paclitaxel; cyclophosphamide; others as listed in Appendix A).
    Appendix B — male agents (examples)Lists chemotherapeutic agents associated with intermediate/high risk to male fertility (examples: carboplatin; cisplatin; cyclophosphamide; carmustine; chlorambucil; others as listed in Appendix B).
    Use in coverage criteriaPlanned chemotherapy with intermediate/high risk per Appendices A & B is an explicit criterion for iatrogenic fertility preservation eligibility.

    Background

    Infertility is defined here as the inability to conceive or carry a pregnancy to live birth after a period of unprotected intercourse without contraception — specifically 12 months for individuals under age 35 or 6 months for those aged 35 or older. Causes of infertility include male factor, ovulation disorders, tubal damage, endometriosis, cervical or coital factors, and unexplained infertility. Evaluation typically follows a stepwise approach based on history and prior results and may include history and physical, targeted laboratory testing (TSH, prolactin, FSH, LH, estradiol, progesterone), pelvic ultrasound, hysterosalpingography, sonohysterography, hysteroscopy, diagnostic laparoscopy, and male evaluation such as semen analysis and endocrine testing. Iatrogenic infertility refers to fertility loss caused by medical treatment (most commonly cancer therapy), and fertility preservation options (including cryopreservation) are considered when planned gonadotoxic therapy is anticipated.

    Revision History